Glucagon-Like Peptide-1 Receptor Agonists and Brain Vascular Function.
Alzheimer's disease
Atherosclerosis
Glucagon-like peptide 1
Neurodegenerative diseases
Therapeutics
Journal
Heart, lung & circulation
ISSN: 1444-2892
Titre abrégé: Heart Lung Circ
Pays: Australia
ID NLM: 100963739
Informations de publication
Date de publication:
Nov 2021
Nov 2021
Historique:
received:
03
05
2021
revised:
14
07
2021
accepted:
21
07
2021
pubmed:
5
9
2021
medline:
6
10
2021
entrez:
4
9
2021
Statut:
ppublish
Résumé
Prevention of cardiovascular events and regression of atherosclerotic changes are the primary aims of preventive cardiovascular medicine. Arterial thrombosis is caused by endothelial dysfunction, which disrupts vascular haemostasis. Glucagon-like peptide 1 (GLP-1) receptor agonists have been initially used as glucose lowering agents, but over time have been used for other indications due to their cardiorenal benefit, as well as their benefit in the regression of atherosclerosis process. The aim of this paper is to present the benefits of GLP-1 receptor agonists in the prevention of atherosclerotic changes, in the preservation of brain vascular function, and to show the possible role in the treatment of neurodegenerative diseases.
Identifiants
pubmed: 34479819
pii: S1443-9506(21)01201-4
doi: 10.1016/j.hlc.2021.07.024
pii:
doi:
Substances chimiques
Cardiovascular Agents
0
Glucagon-Like Peptide-1 Receptor
0
Types de publication
Journal Article
Review
Langues
eng
Sous-ensembles de citation
IM
Pagination
1675-1680Informations de copyright
Copyright © 2021 Australian and New Zealand Society of Cardiac and Thoracic Surgeons (ANZSCTS) and the Cardiac Society of Australia and New Zealand (CSANZ). Published by Elsevier B.V. All rights reserved.